Researchers Submit Patent Application, "Immunoglobulin Expression Levels As Biomarker For Proteasome Inhibitor Response", for Approval (USPTO 20230235406).
In: Hematology Week, 2023-08-17, S. 1895-1895
serialPeriodical
Zugriff:
When the level of Ig expression and/or FCGR2B expression in the sample is less than this reference level, then the patient is administered an alternative anti-tumor therapy that is not a proteasome inhibitor. In exemplary embodiments, the kit comprises one or more binding agents to an Ig gene or gene product, optionally an IgH, IgK or IgL gene segment or gene segment product, and a binding agent to FCGR2B gene or gene product. When the level of Ig expression and/or FCGR2B expression in the sample is less than this reference level, then the treatment regimen preferably includes administration of an alternative anti-tumor therapy that is not a proteasome inhibitor. [Extracted from the article]
Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Immunoglobulin Expression Levels As Biomarker For Proteasome Inhibitor Response", for Approval (USPTO 20230235406).
|
---|---|
Zeitschrift: | Hematology Week, 2023-08-17, S. 1895-1895 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-673X (print) |
Schlagwort: |
|
Sonstiges: |
|